title: [Lymphadenectomy in the surgical treatment of bronchogenic carcinoma].
abstract: Bronchogenic carcinoma is one of the tumors with the statistically most markedly rising incidence, at least in western countries. For many years both the resectability and the long-term results have remained invariable due to the serious delay with which the disease is usually diagnosed. In addition, the success of treatment appears to be closely correlated with disease stage; in particular lymph node involvement has a major influence on the long-term survival following adequate treatment. As a consequence, a strong conviction has established itself in recent years, that radical removal of all mediastinal lymph node stations ipsilateral to the operated lung represents not only a necessary staging procedure, but also a useful measure to improve the prognosis of these patients. However, the real utility of radical lymphadenectomy is questioned by a number of groups: on the one hand the supporters of lymph node "sampling", inasmuch as the usefulness of radical lymphadenectomy has not been demonstrated by randomized clinical trials; on the other hand those workers, in particular from Japan, who on the basis of observations of the lymphatic flow in the mediastinum stress the necessity to extend lymph node clearance to the nodal station contralateral to the tumor. The current opinion is changing under the influence of recent developments, for instance the possible use of the sentinel technique also in lung cancer, and the possibility of "reasonable" or targeted lymphadenectomies, planned in relation to the lobar location of individual tumor. Whichever of these approaches is chosen--and this choice is still a matter of debate--many agree about the importance of neoadjuvant treatment not only to render patients eligible for surgery but also to improve the prognosis for patients at the most advanced stages of the disease.
authors.forename: V
authors.initials: V
authors.lastname: Beltrami
authors.forename: A
authors.initials: A
authors.lastname: Bertagni
authors.forename: M R
authors.initials: MR
authors.lastname: Bosco
authors.forename: A
authors.initials: A
authors.lastname: Covotta
authors.forename: L
authors.initials: L
authors.lastname: Gallinaro
authors.forename: G
authors.initials: G
authors.lastname: Montesano
authors.forename: G A
authors.initials: GA
authors.lastname: Nasti
authors.forename: V
authors.initials: V
authors.lastname: Prece
mesh_terms: D002283:Carcinoma, Bronchogenic / Q000473:pathology / Q000601:surgery*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008197:Lymph Node Excision / Q000379:methods; D008207:Lymphatic Metastasis / Q000175:diagnosis; D009367:Neoplasm Staging; D021701:Sentinel Lymph Node Biopsy; D016019:Survival Analysis; D016896:Treatment Outcome